Peripheral blood serum markers for apoptosis and liver fibrosis: Are they trustworthy indicators of liver realness?

Digestive and Liver Disease

Volumn 40, Issue 6, 2008, Pages 441-445

  Torre, F ^a   Bellis, L ^b   Delfino, A ^a   Pelli, N ^a   Contini, P ^a   Basso, M ^a   Puoti, C ^b   Picciotto, A ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b Marino Hospital Rome   (Italy)

Author keywords

Apoptosis; Fibrosis; Hepatic vein; Hyaluronic acid; Serum markers; sFasL; sHLA I; sTRAIL; TGF 1; TNF

Indexed keywords

BIOLOGICAL MARKER; FAS LIGAND; HLA ANTIGEN CLASS 1; HYALURONIC ACID; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADULT; AGED; APOPTOSIS; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL INDICATOR; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; FEMALE; HEMODYNAMIC MONITORING; HEPATIC VEIN; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; LIVER FIBROSIS; MALE; PERIPHERAL VEIN; PROTEIN BLOOD LEVEL;

ADULT; AGED; APOPTOSIS; BIOLOGICAL MARKERS; FAS LIGAND PROTEIN; FEMALE; HEPATIC VEINS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; HYALURONIC ACID; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 42649087102     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2007.10.027     Document Type: Article

References (30)

1. Standish R.A., Cholongitas E., Dhillon A., Burroughs A.K., and Dhillon A.P. An appraisal of the histopathological assessment of liver fibrosis. Gut 55 (2006) 569-578
2. De Ritis F., Coltorti M., and Giusti G. An enzymic test for the diagnosis of viral hepatitis; the transaminase serum activities. Clin Chim Acta 2 (1957) 70-74
3. Gressner A.M. The cell biology of liver fibrogenesis - an imbalance of proliferation, growth arrest and apoptosis of myofibroblasts. Cell Tissue Res 292 (1998) 447-452
4. Armendariz-Borunda J., Katayama K., and Seyer J.M. Transcriptional mechanisms of type I collagen gene expression are differentially regulated by interleukin-1 beta, tumor necrosis factor alpha, and transforming growth factor beta in Ito cells. J Biol Chem 267 (1992) 14316-14321
5. Bissell D.M., Wang S.S., Jarnagin W.R., and Roll F.J. Cell-specific expression of transforming growth factor-beta in rat liver. Evidence for autocrine regulation of hepatocyte proliferation. J Clin Invest 96 (1995) 447-455
6. Powell E.E., Edwards-Smith C.J., Hay J.L., Clouston A.D., Crawford D.H., Shorthouse C., et al. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 31 (2000) 828-833
7. Olaso E., and Friedman S.L. Molecular regulation of hepatic fibrogenesis. J Hepatol 29 (1998) 836-847
8. Gressner A.M., and Weiskirchen R. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. J Cell Mol Med 10 (2006) 76-99
9. Murawaki Y., Nishimura Y., Ikuta Y., Idobe Y., Kitamura Y., and Kawasaki H. Plasma transforming growth factor-beta 1 concentrations in patients with chronic viral hepatitis. J Gastroenterol Hepatol 13 (1998) 680-684
10. Pares A., Deulofeu R., Gimenez A., Caballeria L., Bruguera M., Caballeria J., et al. Serum hyaluronate reflects hepatic fibrogenesis in alcoholic liver disease and is useful as a marker of fibrosis. Hepatology 24 (1996) 1399-1403
11. Schulze-Bergkamen H., Schuchmann M., Fleischer B., and Galle P.R. The role of apoptosis versus oncotic necrosis in liver injury: facts or faith?. J Hepatol 44 (2006) 984-993
12. Canbay A., Friedman S., and Gores G.J. Apoptosis: the nexus of liver injury and fibrosis. Hepatology 39 (2004) 273-278
13. Reed J.C. Mechanisms of apoptosis. Am J Pathol 157 (2000) 1415-1430
14. Natali P.G., Bigotti A., Nicotra M.R., Viora M., Manfredi D., and Ferrone S. Distribution of human class I (HLA-A,B,C) histocompatibility antigens in normal and malignant tissues of nonlymphoid origin. Cancer Res 44 (1984) 4679-4687
15. Hagihara M., Shimura T., Yamamoto K., Sujirachato K., Tsuji S., Yamamura M., et al. Clinical significance of serum soluble HLA class I antigens in systemic lupus erythematosus. Tokai J Exp Clin Med 18 (1993) 61-64
16. Puppo F., Torre F., Contini P., Ghio M., Brenci S., Brizzolara R., et al. Soluble beta2-mu-associated and beta2-mu-free HLA class I heavy chain serum levels in interferon-alpha nonresponder chronic hepatitis C patients. Markers of immune activation, and response to antiviral retreatment. J Clin Immunol 20 (2000) 486-490
17. Bai J., and Odin J. Apoptosis and the liver: relation to autoimmunity and related conditions. Autoimmun Rev 2 (2003) 36-42
18. Gruss H. Molecular, structural, and biological characteristics of the tumor necrosis factor ligand superfamily. Int J Clin Lab Res 26 (1996) 143-159
19. Zheng S.J., Wang P., Tsabary G., and Chen Y.H. Critical roles of TRAIL in hepatic cell death and hepatic inflammation. J Clin Invest 113 (2004) 58-64
20. Ashkenazi A., Pai R.C., Fong S., Leung S., Lawrence D.A., Marsters S.A., et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104 (1999) 155-162
21. Sheridan J.P., Marsters S.A., Pitti R.M., Gurney A., Skubatch M., Baldwin D., et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277 (1997) 818-821
22. Wiley S.R., Schooley K., Smolak P.J., Din W.S., Huang C.P., Nicholl J.K., et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3 (1995) 673-682
23. Lunemann J.D., Waiczies S., Ehrlich S., Wendling U., Seeger B., Kamradt T., et al. Death ligand TRAIL induces no apoptosis but inhibits activation of human (auto)antigen-specific T cells. J Immunol 168 (2002) 4881-4888
24. Ghio M., Contini P., Mazzei C., Brenci S., Barberis G., Filaci G., et al. Soluble HLA class I, HLA class II, and Fas ligand in blood components: a possible key to explain the immunomodulatory effects of allogeneic blood transfusions. Blood 93 (1999) 1770-1777
25. Wang X., Chen Y.X., Xu C.F., Zhao G.N., Huang Y.X., and Wang Q.L. Relationship between tumor necrosis factor-alphaand liver fibrosis. World J Gastroenterol 4 (1998) 18
26. Sacco R., Leuci D., Tortorella C., Fiore G., Marinosci F., Schiraldi O., et al. Transforming growth factor beta1 and soluble Fas serum levels in hepatocellular carcinoma. Cytokine 12 (2000) 811-814
27. Parise E.R., Oliveira A.C., Figueiredo-Mendes C., Lanzoni V., Martins J., Nader H., et al. Noninvasive serum markers in the diagnosis of structural liver damage in chronic hepatitis C virus infection. Liver Int 26 (2006) 1095-1099
28. Pelli N., Floreani A., Torre F., Delfino A., Baragiotta A., Contini P., et al. Soluble apoptosis molecules in primary biliary cirrhosis: analysis and commitment of the Fas and tumour necrosis factor-related apoptosis-inducing ligand systems in comparison with chronic hepatitis C. Clin Exp Immunol 148 (2007) 85-89
29. McDonald J.C. Adamashvili I. Soluble HLA: a review of the literature. Hum Immunol 59 (1998) 387-403
30. Chaudry I.H., Zellweger R., and Ayala A. The role of bacterial translocation on Kupffer cell immune function following hemorrhage. Prog Clin Biol Res 392 (1995) 209-218